Last Modified: November 1, 2001
Last Updated: 2001-01-29 19:30:25 EST (Reuters Health) - ProstaScint imaging (Cytogen, Princeton, New Jersey) provides complementary information to prostate-specific antigen (PSA) level and Gleason scores in predicting prostate cancer recurrence and metastases, Ohio researchers report.
Dr. D. B. Sodee and colleagues at Case Western Reserve University in Cleveland retrospectively examined 2290 ProstaScint scans of 2154 patients with prostate cancer, performed at 15 institutions over a 3-year period.
They stratified the patients into four groups: those who were newly diagnosed (group 1), those who had a rising PSA level after radical prostatectomy (group 2), those who had a rising PSA level after radiation therapy (group 3), and those who had undergone hormonal therapy (group 4).
The authors explain that in group 1, there was significant correlation of PSA level with positive ProstaScint scans of the prostate bed and ProstaScint detection of pelvic metastases, but not extrapelvic metastases. Among group 2 patients, "the association for detecting fossa recurrence was weaker and was insignificant for pelvic and extrapelvic metastases," they write in the December issue of Urology.
According to the report, in group 3 there was a weak association between PSA level and ProstaScint detection of fossa recurrence. The association was insignificant for pelvic and extrapelvic metastases in these patients. Among patients in group 4, the investigators observed no significant correlation between PSA and ProstaScint results.
For all groups, the researchers note, the distribution of positive ProstaScint results among the prostate/prostate bed, pelvic nodes and extrapelvic nodes was almost equal. In group 4, however, they observed a significantly greater percentage of extrapelvic metastases. "The ProstaScint results were independent of the Gleason score for 260 patients before and 285 patients after therapy."
Dr. Sodee and colleagues conclude, "The statistical similarity of pelvic and extrapelvic abnormal foci in the pretherapy and the post-therapy prostate cancer groups indicates that ProstaScint imaging provides valuable information, with the potential to aid both urologists and oncologists in the staging and treatment of prostate cancer."